MK-801 처치와 지구성 훈련이 심근의 혈관생성 반응에 미치는 영향 = Effect of MK-801 Treatment and Endurance Training on Angiogenic Response in Cardiac Muscle

다국어 초록 (Multilingual Abstract)

PURPOSE: The purpose of this study was to investigate the effects of regular endurance exercise on the changes of angiogenic biomarkers in myocardial tissues of the schizophrenia-induced rats.
METHODS: Twenty-one SD rats were randomly assigned to CON (n=7), MK (n=7) and MK+ET (n=7) groups. MK and MK+ET groups were treated with MK-801 for 2 weeks before endurance training. MK+ET group ran on a rodent treadmill at 22 m/min for 4 weeks (5 days/week, 30 min/day) after the treatment. Protein expressions of NMDA receptor and angiogenic factors (HIF-1α, VEGF, Flk-1, Ang-1,-2) in myocardial tissue were analyzed by western blot.
RESULTS: Expression of NMDA receptor (p=.004), VEGF (p=.016), Flk-1 (p=.001), Ang-1 (p=.001), Ang-2 (p=.015) in MK group were significantly lower than in CON group. On contrary, MK+ET group showed no significant expression of NMDA receptor, VEGF and Flk-1 compared to CON group (p>.05). Ang-1 (p=.001) and Ang-2 (p=.001) expression of MK+ET group were significantly lower than those of CON group, whereas Ang-1 expression in MK+ET (p=.024) group was higher than that of MK group. In addition, Ang-2: Ang-1 ratio in MK (p=.001) group was significantly higher than in CON group, however there was no difference between CON and MK+ET group (p>.05).
CONCLUSIONS: These results suggest that the reduction of NMDA receptors by MK-801 may negatively affect the angiogenic responses in myocardial tissue and that regular endurance exercise may have the effect of improving them.

참고문헌 (Reference)

1 Murphy BP, "Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis" 2014 : 719395-, 2014

2 박준기, "Treadmill exercise enhances NMDA receptor expression in schizophrenia mice" 한국운동재활학회 10 (10): 15-21, 2014

3 Kimhy D, "The impact of aerobic exercise on brain-derived neurotrophic factor and neurocognition in individuals with schizophrenia : a single-blind, randomized clinical trial" 41 (41): 859-868, 2015

4 Jones N, "Tek/Tie2 signaling : new and old partners" 19 : 13-17, 2000

5 Rosano JM, "Targeted delivery of VEGF after a myocardial infarction reduces collagen deposition and improves cardiac function" 3 : 237-247, 2012

6 Manu P, "Sudden deaths in psychiatric patients" 72 (72): 936-941, 2011

7 Abraham D, "Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy" 87 : 644-647, 2000

8 von Hausswolff-Juhlin Y, "Schizophrenia and physical health problems" (438) : 15-21, 2009

9 Hennekens CH, "Schizophrenia and increased risks of cardiovascular disease" 150 (150): 1115-1121, 2005

10 Palomino A, "Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients" 44 : 29-33, 2013

11 Siddiqui NI, "Regular physical exercise : way to healthy life" 19 : 154-158, 2010

12 Merenmies J, "Receptor tyrosine kinase signaling in vascular development" 8 : 3-10, 1997

13 Ong T, "Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients" 38 (38): 1845-1851, 2010

14 Vancampfort D, "Promotion of cardiorespiratory fitness in schizophrenia : a clinical overview and meta-analysis" 132 (132): 131-143, 2015

15 Swain RA, "Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat" 117 (117): 1037-1046, 2003

16 Hein S, "Progression from compensated hypertrophy to failure in the pressure-overloaded human heart : structural deterioration and compensatory mechanisms" 107 : 984-991, 2003

17 Olfson M, "Premature mortality among adults with schizophrenia in the United States" 72 (72): 1172-1181, 2015

18 Yoon S, "Preliminary effectiveness and sustainability of group aerobic exercise program in patients with schizophrenia" 204 (204): 644-650, 2016

19 Takebayashi M, "Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders" 117 (117): 1119-1122, 2010

20 Rosenbaum S, "Physical activity interventions for people with mental illness : a systematic review and meta-analysis" 75 (75): 964-974, 2014

21 Li JT, "Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats" 652 (652): 65-72, 2011

22 Carlsson A, "Neurotransmitter interactions in schizophrenia-therapeutic implications" 249 (249): 37-43, 1999

23 Snyder MA, "NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia" 7 : 31-, 2013

24 Kaul S, "Myocardial capillaries and coronary flow reserve" 52 : 1399-1401, 2008

25 Gale CR, "Mental disorders across the adult life course and future coronary heart disease : evidence for general susceptibility" 129 (129): 186-193, 2014

26 Li F, "Memory and the NMDA receptors" 361 (361): 302-303, 2009

27 Yu J, "MK-801 induces schizophrenic behaviors through downregulating Wnt signaling pathways in male mice" 1385 : 281-292, 2011

28 Gill C, "Losing heart: the role of apoptosis in heart disease--a novel therapeutic target?" 16 (16): 135-146, 2002

29 Laursen TM, "Life expectancy and cardiovascular mortality in persons with schizophrenia" 25 : 83-88, 2012

30 Carlsson M, "Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson’s disease" 13 (13): 272-276, 1990

31 Lee BH, "Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders" 136 (136): 181-184, 2012

32 Lou SJ, "Hippocampal neurogenesis and gene expression depend on exercise intensity in juvenile rats" 1210 : 48-55, 2008

33 Gale NW, "Growth factors acting via endothelial cellspecific receptor tyrosine kinases : VEGFs, angiopoietins, and ephrins in vascular development" 13 (13): 1055-1066, 1999

34 Coyle JT, "Glutamate and schizophrenia: beyond the dopamine hypothesis" 26 (26): 365-384, 2006

35 Sawano A, "Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans" 97 (97): 785-791, 2001

36 Wu G, "Exercise-induced expression of VEGF and salvation of myocardium in the early stage of myocardial infarction" 296 (296): H389-H395, 2009

37 Iemitsu M, "Exercise training improves aging-induced downregulation of VEGF angiogenic signaling cascade in hearts" 291 (291): H1290-H1298, 2006

38 Shiojima I, "Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure" 115 : 2108-2118, 2005

39 Fulzele S, "Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects" 115 (115): 372-373, 2009

40 Lim AL, "Consequences of early life MK-801administration : long-term behavioural effects and relevance to schizophrenia research" 227 (227): 276-286, 2012

41 Harvey PD, "Cognitive functioning in schizophrenia : a consensus statement on its role in the definition and evaluation of effective treatments for the illness" 65 (65): 361-372, 2004

42 Bellani M, "Cerebellar and lobar blood flow in schizophrenia : a perfusion weighted imaging study" 193 (193): 46-52, 2011

43 Brown S, "Causes of the excess mortality of schizophrenia" 177 : 212-217, 2000

44 Lewis SJ, "Cardiovascular effects of the N-methyl-D-aspartate receptor antagonist MK-801 in conscious rats" 13 (13): 759-765, 1989

45 Green MF, "Approaching a consensus cognitive battery for clinical trials in schizophrenia:the NIMH-MATRICS conference to select cognitive domains and test criteria" 56 (56): 301-307, 2004

46 Kimhy D, "Aerobic fitness and body mass index in individuals with schizophrenia : Implications for neurocognition and daily functioning" 220 (220): 784-791, 2014

47 Saha S, "A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?" 64 (64): 1123-1131, 2007

48 Firth J, "A systematic review and metaanalysis of exercise interventions in schizophrenia patients" 45 (45): 1343-1361, 2015

49 De Rossi P, "A critical role for VEGF and VEGFR2 in NMDA receptor synaptic function and fear-related behavior" 21 (21): 1768-1780, 2016

50 Goff DC, "A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls" 80 (80): 45-53, 2005